Periostin in Inflammatory Bowel Disease (IBD) development and synergistic effects mediated via CCL5

Simple item page
dc.contributor.authorRiethmacher, Eva
dc.contributor.authorVangelista, Luca
dc.contributor.authorMukanova, Saida
dc.contributor.authorRiethmacher, Dieter
dc.date.accessioned2018-11-01T03:50:30Z
dc.date.available2018-11-01T03:50:30Z
dc.date.issued2018-10-18
dc.description.abstractThe incidence of IBD is rising all over the world and is affecting 1 in 4000 people in Europe and 1 in 16.000 in Asia. [1] Welldocumented, reliable numbers for Kazakhstan are currently not available but observations from local physicians (personal communication) suggest that numbers might be significantly higher than suggested by the literature. The matricellular protein Periostin has recently been shown to be involved in IBD [2] (and our own unpublished data). In a chemically induced murine model (dextrane sulfate sodium DSS) it mediates intestinal inflammation through the activation of NF-κB signaling, which suggests that periostin is a potential therapeutic target for inflammatory bowel disease [2]. CCL5, also know as RANTES, is a chemokine shown to be interacting with the G protein-coupled receptors CCR1, CCR3 and CCR5 [3]. In a recent study it could be shown that CCR5 expression correlates with the infiltration of inflammatory cells into the lamina propria of IBD patients [4]. Periostin is a matricellular protein originally isolated from osteoblasts and found to be preferentially expressed in the periosteum [5, 6]. Periostin contains an N-terminal secretory signal peptide, followed by a cysteine-rich domain, four internal homologous repeats, and a C-terminal hydrophilic domain. The four internal repeats exhibit homology to the axon guidance protein fasciclin I that is involved in the development of nervous system in invertebrates and were thus named fasciclin domains.en_US
dc.identifier.citationRiethmacher, Eva et al. (2018) Periostin in Inflammatory Bowel Disease (IBD) development and synergistic effects mediated via CCL5. Nazarbayev Universityen_US
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/3581
dc.language.isoenen_US
dc.publisherNazarbayev Universityen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectchemokine receptors (CCRs)en_US
dc.subjectINFLAMMATORY BOWEL DISEASE (IBD)en_US
dc.titlePeriostin in Inflammatory Bowel Disease (IBD) development and synergistic effects mediated via CCL5en_US
dc.typePresentationen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
29 -Dieter Riethmacher-DINA0 - Dieter Riethmacher.pdf
Size:
2.06 MB
Format:
Adobe Portable Document Format
Description:
Poster
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

NU Research Week - 2018